Objectives: The objective was to compare specific data from the 2020 National Confidential Enquiry into Patient Outcome and Death (NCEPOD) report "Balancing the Pressures" with two previous U.K. studies and to examine changes in the pediatric population requiring long-term ventilation (LTV) as well as the types delivered. We believe that the new data presented will facilitate future service planning.
Design: A subset of confidential enquiry data derived from a study by a nationally funded quality improvement organization (NCEPOD: www.ncepod.org.uk ) was compared with two previous U.K. datasets.
Setting: Healthcare providers across England, Wales, and Northern Ireland-inpatient and community settings.
Patients: Children and young people (CAYP) 0-16 years old receiving LTV between April 1, 2016, and March 31, 2018.
Interventions: None.
Measurements And Main Results: When comparing the NCEPOD data with that last published in the United Kingdom, the number of CAYP requiring LTV more than doubled between 2008 and 2018 (933-2,093). There has also been a particular increase in the proportion of children that were under two when they were commenced on LTV (26-39.2%). Children are now more likely than previously to be receiving LTV to manage upper airway obstruction and CNS conditions. There has also been an approximate doubling of those receiving LTV over the whole 24-hour period (9.4-18.4%).
Conclusions: The increased numbers and changing characteristics of babies and children requiring LTV over the last 3 decades in the United Kingdom have implications for all healthcare sectors but particularly for providers of critical care services.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1097/PCC.0000000000003253 | DOI Listing |
Transplant Cell Ther
December 2024
Infectious Diseases Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York; Adult Bone Marrow Transplantation Service, Memorial Sloan Kettering Cancer Center, New York, New York. Electronic address:
We evaluated letermovir (LTV) for secondary prophylaxis for cytomegalovirus (CMV) in allogeneic hematopoietic cell transplant recipients (HCT) at high-risk for CMV recurrence. This open-label study was conducted at Memorial Sloan Kettering Cancer Center and the University of Minnesota. Patients with clinically significant CMV infection (cs-CMVi) and ≥1 high-risk criteria for CMV who achieved viral suppression with standard CMV antivirals received LTV secondary prophylaxis for up to 14 weeks.
View Article and Find Full Text PDFJ Infect Chemother
December 2024
Department of Hematology/Oncology, Kurashiki Central Hospital, 1-1-1 Miwa, Kurashiki, 710-8602, Japan.
Clin Transplant
December 2024
Division of Pulmonary and Critical Care, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
Background: Cytomegalovirus (CMV) is associated with detrimental outcomes after lung transplantation (LTX); primary prophylaxis (PPX) with valganciclovir (VGC) is guideline-recommended. VGC is associated with myelosuppression, spurring interest in letermovir (LTV).
Methods: Adults undergoing LTX between January 1, 2021, and July 30, 2022 at our institution who were converted from VGC to LTV for PPX were evaluated.
J Hematol Oncol
October 2024
National Clinical Research Center for Hematologic Diseases, the First Affiliated Hospital of Soochow University, Suzhou, 215006, Jiangsu, China.
Chest
September 2024
School of Biomedical Engineering, Guangzhou Medical University, Guangzhou, Guangdong, China; Institute of Technical Medicine, Furtwangen University, Villingen-Schwenningen, Germany.
Background: The physiologic effects of different ventilation strategies on patients with ARDS need to be better understood.
Research Question: In patients with ARDS receiving controlled mandatory ventilation, does airway pressure release ventilation (APRV) improve lung ventilation/perfusion (V˙/Q˙) matching and ventilation homogeneity compared with low tidal volume (LTV) ventilation?
Study Design And Methods: This study was a single-center randomized controlled trial. Patients with moderate to severe ARDS were ventilated randomly with APRV or LTV ventilation.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!